Dianomi Therapeutics will work with Ligand on a medication delivery platform based on research from University of Wisconsin-Madison initially targeting pain disorders and osteoarthritis.
Dianomi Therapeutics, a US-based osteoarthritis treatment technology developer based on University of Wisconsin-Madison (UW-Madison) research, obtained $3m in funding on Tuesday under a partnership deal with biotech developer Ligand Pharmaceuticals. Founded in 2017, Dianomi Therapeutics has licensed a therapeutics delivery technology called Mineral Coated Microparticle (MCM) that sustains biologics and small molecules in the body…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
